Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of 9-valent HPV vaccination on disease burden in patients with actinic keratosis
2021-003895-15Phase 2Completed
- Sponsor
- Bispebjerg and Frederiksberg Hospital
- Start
- Oct 2021
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in actinic keratosis (AK) and cutaneous premalignancy comparing Gardasil 9 vaccination with Placebo / control (2 arms). Primary endpoints: Impact of HPV vaccination on actinic keratosis burden and development over 12 months and Local and systemic side effects over 12 months. Started Oct 2021; status: completed.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
actinic keratosis (AK)cutaneous premalignancy
Beyond the preview
Go deeper on 2021-003895-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003895-15.